24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
Do you want to feel valued for who you really are? Oxford PharmaGenesis will be at the Working in and around #MedComms careers event! Whether you’re new to medical communications or looking to advance your career, we want to hear about your unique skills and experience. Visit our booth to chat about our award-winning HealthScience consultancy, plus our exciting roles, development opportunities and one-of-a-kind company culture.
Oxford PharmaGenesis is delighted to support a funded DPhil studentship in Translational Health Sciences in collaboration with Green Templeton College at the University of Oxford, UK. The studentship will examine the importance of diversity in dermatology, particularly when applying emerging techniques in artificial intelligence and machine learning. Applications are now open. Please help to spread…
For the second year running, media brand Medical Marketing and Media (MM+M) has listed Oxford PharmaGenesis in its Agency 100 report – the annual definitive ‘who’s who’ ranking of the healthcare sector’s top marketing firms in North America.
Oxford PharmaGenesis is proud to sponsor the latest CISCRP clinical trials education campaign to raise awareness and understanding of clinical research among minority urban communities in cities across the USA and among the wider general public.
Oxford PharmaGenesis has been shortlisted for the Communiqué Awards 2022 for the Award for Excellence in Public Health Communications for MS Brain Health, on behalf of Oxford Health Policy Forum. This global policy initiative has changed the way that leading multiple sclerosis (MS) experts view best practice in MS care.
Citation (title and abstract) screening for a systematic literature review may be accelerated by 25% through the application of artificial intelligence (AI) in a novel method developed by Oxford PharmaGenesis in partnership with Vyasa. The evidence reported in systematic literature reviews derives from articles that have passed a rigorous screening process. According to a recent study, our new,…
